guest ::
| Home > Publications database > Is HLA type a possible cancer risk modifier in Lynch syndrome? > print |
| Home > Publications database > Is HLA type a possible cancer risk modifier in Lynch syndrome? > print |
| 001 | 182209 | ||
| 005 | 20240229145713.0 | ||
| 024 | 7 | _ | |a 10.1002/ijc.34312 |2 doi |
| 024 | 7 | _ | |a pmid:36214792 |2 pmid |
| 024 | 7 | _ | |a 0020-7136 |2 ISSN |
| 024 | 7 | _ | |a 1097-0215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:136998060 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02503 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ahadova, Aysel |0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Is HLA type a possible cancer risk modifier in Lynch syndrome? |
| 260 | _ | _ | |a Bognor Regis |c 2023 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1678877599_29492 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F210#LA:F210# / 2023 May 15;152(10):2024-2031 |
| 520 | _ | _ | |a Lynch syndrome (LS) is the most common inherited cancer syndrome. It is inherited via a monoallelic germline variant in one of the DNA mismatch repair (MMR) genes. LS carriers have a broad 30% to 80% risk of developing various malignancies, and more precise, individual risk estimations would be of high clinical value, allowing tailored cancer prevention and surveillance. Due to MMR deficiency, LS cancers are characterized by the accumulation of frameshift mutations leading to highly immunogenic frameshift peptides (FSPs). Thus, immune surveillance is proposed to inhibit the outgrowth of MMR-deficient cell clones. Recent studies have shown that immunoediting during the evolution of MMR-deficient cancers leads to a counter-selection of highly immunogenic antigens. The immunogenicity of FSPs is dependent on the antigen presentation. One crucial factor determining antigen presentation is the HLA genotype. Hence, a LS carrier's HLA genotype plays an important role in the presentation of FSP antigens to the immune system, and may influence the likelihood of progression from precancerous lesions to cancer. To address the challenge of clarifying this possibility including diverse populations with different HLA types, we have established the INDICATE initiative (Individual cancer risk by HLA type, http://indicate-lynch.org/), an international network aiming at a systematic evaluation of the HLA genotype as a possible cancer risk modifier in LS. Here we summarize the current knowledge on the role of HLA type in cancer risk and outline future research directions to delineate possible association in the scenario of LS with genetically defined risk population and highly immunogenic tumors. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a HLA genotype |2 Other |
| 650 | _ | 7 | |a Lynch syndrome |2 Other |
| 650 | _ | 7 | |a cancer immunoediting |2 Other |
| 650 | _ | 7 | |a immune surveillance |2 Other |
| 650 | _ | 7 | |a personalized cancer risk |2 Other |
| 700 | 1 | _ | |a Witt, Johannes |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Haupt, Saskia |b 2 |
| 700 | 1 | _ | |a Gallon, Richard |b 3 |
| 700 | 1 | _ | |a Hüneburg, Robert |b 4 |
| 700 | 1 | _ | |a Nattermann, Jacob |b 5 |
| 700 | 1 | _ | |a Ten Broeke, Sanne |b 6 |
| 700 | 1 | _ | |a Bohaumilitzky, Lena |0 P:(DE-He78)a7f54298fcba548e34453b02202e6519 |b 7 |u dkfz |
| 700 | 1 | _ | |a Hernandez-Sanchez, Alejandro |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Santibanez-Koref, Mauro |b 9 |
| 700 | 1 | _ | |a Jackson, Michael S |b 10 |
| 700 | 1 | _ | |a Ahtiainen, Maarit |b 11 |
| 700 | 1 | _ | |a Pylvänäinen, Kirsi |b 12 |
| 700 | 1 | _ | |a Andini, Katarina |b 13 |
| 700 | 1 | _ | |a Grolmusz, Vince Kornel |b 14 |
| 700 | 1 | _ | |a Möslein, Gabriela |b 15 |
| 700 | 1 | _ | |a Dominguez-Valentin, Mev |0 0000-0001-7856-0057 |b 16 |
| 700 | 1 | _ | |a Møller, Pål |b 17 |
| 700 | 1 | _ | |a Fürst, Daniel |b 18 |
| 700 | 1 | _ | |a Sijmons, Rolf |b 19 |
| 700 | 1 | _ | |a Borthwick, Gillian M |b 20 |
| 700 | 1 | _ | |a Burn, John |b 21 |
| 700 | 1 | _ | |a Mecklin, Jukka-Pekka |b 22 |
| 700 | 1 | _ | |a Heuveline, Vincent |b 23 |
| 700 | 1 | _ | |a von Knebel Doeberitz, Magnus |0 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |b 24 |u dkfz |
| 700 | 1 | _ | |a Seppälä, Toni |b 25 |
| 700 | 1 | _ | |a Kloor, Matthias |0 P:(DE-He78)3121b75683af3772ca9289d447889ed9 |b 26 |e Last author |
| 773 | _ | _ | |a 10.1002/ijc.34312 |g p. ijc.34312 |0 PERI:(DE-600)1474822-8 |n 10 |p 2024-2031 |t International journal of cancer |v 152 |y 2023 |x 0020-7136 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:182209 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)a7f54298fcba548e34453b02202e6519 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)3121b75683af3772ca9289d447889ed9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-02-04 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2022 |d 2023-10-21 |
| 920 | 2 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)F210-20160331 |k F210 |l KKE Angewandte Tumorbiologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F210-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|